Immatics (IMTX)

• Market cap: $1.45B
• 1 day: -1.82%
• 5 days: -5.35%
• 1 month: 7.79%
• 3 months: 8.01%
• 6 months: 11.47%
• Year to date: 3.25%
• 1 year: 115.37%
• 5 years: -13.33%
• 10 years: 12.4%
• Sector: Healthcare
• Industry: Biotechnology

About: Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Employees: 407